Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 261 results for carcinoma

  1. Flexible endoscopic treatment of a pharyngeal pouch (IPG513)

    Evidence-based recommendations on flexible endoscopic treatment of a pharyngeal pouch. This involves improving swallowing by widening the neck of the pouch so that food does not collect in it.

  2. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development Reference number: GID-TA10745 Expected publication date:  17 July 2024

  3. Catheterless oesophageal pH monitoring (IPG187)

    Evidence-based recommendations on catheterless oesophageal pH monitoring. This involves placing a small wireless capsule in the gullet to check the level of acid.

  4. Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy ID940

    Discontinued Reference number: GID-TA10397

  5. Birch bark extract for treating epidermolysis bullosa (HST28)

    Evidence-based recommendations on birch bark extract (Filsuvez) for treating partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in people aged 6 months and over.

  6. Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

    Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a high risk of recurrence, in adults.

  7. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)

    Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults.

  8. Photodynamic therapy for early-stage oesophageal cancer (IPG200)

    Evidence-based recommendations on photodynamic therapy for early-stage oesophageal cancer. This involves injecting a photosensitising agent into the tumour which is then activated by a light to destroy the tumour cells.

  9. Stent placement for vena caval obstruction (IPG79)

    Evidence-based recommendations on stent placement for vena caval obstruction. This involves using a catheter to position a stent, which may be self-expanding or balloon-dilated, across the area of narrowing to relieve it.

  10. Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]

    Discontinued Reference number: GID-TAG398

  11. Irreversible electroporation for primary liver cancer (IPG664)

    Evidence-based recommendations on irreversible electroporation for primary liver cancer in adults. This involves passing short electrical pulses of high-voltage current into the cancer cells.

  12. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    Discontinued Reference number: GID-TA11008

  13. Laparoscopic liver resection (IPG135)

    Evidence-based recommendations on laparoscopic liver resection. This involves making small incisions (keyhole surgery) to remove the parts of the liver that are benign or cancerous.

  14. Interstitial photodynamic therapy for malignant parotid tumours (IPG259)

    Evidence-based recommendations on interstitial photodynamic therapy for malignant parotid tumours. This involves injecting a photosensitising agent into a vein and using a special light to activate it and destroy the tumour cells.